Upstream Bio, Inc.
upstreambio.comWhat Do They Do?
Develops verekitug, an antibody treatment candidate for severe asthma, chronic rhinosinusitis with nasal polyps, and COPD.
10-K for FY2025, filed Mar 26, 2026We are a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory…View ↗
How Do They Make Money?
Maruho reimburses the company for research and development work and drug supply in Japan; Upstream Bio earns revenue as it carries out that work.
10-K for FY2025, filed Mar 26, 2026
$2.9M
-
10-K for FY2025, filed Mar 26, 2026
$2.9M ↗
Who Are Their Customers?
Maruho contracts with Upstream Bio for research and development work in Japan and drug supply, reimbursing the associated costs.
10-K for FY2025, filed Mar 26, 2026
Do Revenues Turn Into Profits?
No. It lost $143.4M in FY2025.
10-K for FY2025, filed Mar 26, 2026
−$160.4MView ↗
10-K for FY2025, filed Mar 26, 2026
−$143.4MView ↗
10-K for FY2025, filed Mar 26, 2026
−$133.4MView ↗
How Are They Changing?
Who Do They Compete With?
Competes with Genentech, Novartis, Sanofi, Regeneron, GSK, AstraZeneca, and Amgen
10-K for FY2025, filed Mar 26, 2026Existing therapeutics for asthma include controller medications, reliever medications and more recently, biologics from Genentech, Inc.…View ↗
Loading...
